Breaking: FDA sidelines Paul Hudson's $3.7B MS drug after establishing link to liver damage - Endpoints News
6/30/2022 12:00:00 AM3 years 8 months ago
by John Carroll
by John Carroll
One of Sanofi CEO Paul Hudson's top picks in the pipeline — picked up in a $3.7 billion buyout 2 years ago — has just been sidelined in the US by a safety issue. The pharma giant put out word early Thursday that the FDA has put their Phase III
We now know the number of jobs coming under the axe at Novartis, and it isn’t small. The pharma giant is confirming a report from Swiss newspaper Tages-Anzeiger that it is chopping 8,000 jobs out of… [+490 chars]
full article...